Pfizer (PFE.US) splurged billions of dollars to acquire Metsera (MTSR.US), while Novo Nordisk (NVO.US) decided to not increase their investment.

According to the Wise Finance app, Novo Nordisk (NVO.US) has decided not to submit a new acquisition offer in the process of bidding for the biotechnology company Metsera (MTSR.US). The acquisition was ultimately completed by Pfizer (PFE.US) for approximately 10 billion US dollars, serving as a stepping stone for its entry into the weight loss drug market.